Company: OSRH
Filing Date: 2025-06-23
Form Type: 424B3
Source: 0001213900-25-056351
Chunk: 18

Company: OSR Holdings, Inc.
Filing Date: 2025-06-23
Form: 424B3
Chunk 18
---
center'>10</div>

Manufacturing

We do not have any manufacturing facilities or
personnel at this time, except that Darnatein maintains and uses manufacturing facilities owned by Joint Center for Biosciences, Darnatein’s
affiliate and the Company’s shareholder, for purposes of R&D and clinical and preclinical materials for its sole use. We currently
rely on CMOs for the manufacture of our product candidates for preclinical and clinical testing in non-commercial quantities.

Our product candidates include small molecules,
vaccines, and monoclonal and bispecific antibodies. Several contract manufacturing facilities exist that have expertise in each product
type and we anticipate that our product candidates can be produced by them at scale and in a cost-effective manner. As needed, we
also expect to rely on CMOs for the manufacturing of companion diagnostics, which are assays or tests to identify an appropriate patient
population. Depending on the technology solutions we choose, we may rely on multiple third parties to manufacture and sell a single test.

Vaximm has a master service agreement with Richter-Helm BioLogics
GmbH & Co. KG (“RHB”), a CMO located in Germany, for the manufacture of Vaximm’s product candidates. RHB will
provide cell line development, process development, manufacturing, and related services for Vaximm’s product candidates. The agreement
became effective April 10, 2012, and will remain in effect until terminated by either party. Vaximm pays RHB for services rendered
based on agreed-upon rates specified in individual work orders. Vaximm retains ownership of all intellectual property related to
its product candidates, while RHB owns IP related to manufacturing processes developed under the agreement.

Commercialization

We will objectively assess and choose each program’s
commercialization option that maximizes potential value for patients and for our stockholders. We anticipate optimizing commercial value
through various options, including internal advancement, strategic partnerships, and spin-outs or public offerings. If we opt to
commercialize a particular candidate ourselves, we anticipate assembling a commercialization team inclusive of sales and marketing operations
to promote and sell our products. Our focus will be the community of relevant medical practitioners who are the key specialists in treating
the patient populations for which our product candidates are being developed. We may also enter into distribution and other marketing
arrangements with third parties for any of our product candidates that obtain marketing approval.

We currently do not have marketing and sales
management operations for